The results of in vivo detection markers, including PTGS2 mRNA levels and MDA quantification, suggested that knocking down BMAL1 increased tumor cell susceptibility to ferroptosis (Fig. 7C, D). The gene discussed is PTGS2; the disease is neoplasm.